11-23-2020, 11:51 AM
The AstraZeneca/Oxford vaccine that was announced today is pretty promising, doesn't need super-cold storage and is much less expensive, maybe a tenth of the cost of an mRNA shot. But even fewer details are available, on storage and side effects, for example.
Their trial size was only about 11,000 people, and of those, half got the placebo (meningitis shot), (maybe) a quarter got the COVID in two full-size inoculations, and (maybe) a quarter got it in a half-size and then full-size. The full/full was 62% efficacy and half/full was 90%, but effectively those are now quite small trials, each with fewer than 10,000 people (details not provided). In comparison, Moderna's trial has 30,000 people and the Pfizer/BioNTech has 39,000.
It's still good news, but I really want to see more details.
Their trial size was only about 11,000 people, and of those, half got the placebo (meningitis shot), (maybe) a quarter got the COVID in two full-size inoculations, and (maybe) a quarter got it in a half-size and then full-size. The full/full was 62% efficacy and half/full was 90%, but effectively those are now quite small trials, each with fewer than 10,000 people (details not provided). In comparison, Moderna's trial has 30,000 people and the Pfizer/BioNTech has 39,000.
It's still good news, but I really want to see more details.